New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2014
09:01 EDTSGENSeattle Genetics announces ADCETRIS approval in Japan
Seattle Genetics announced that its collaborator, Takeda Pharmaceutical Company Limited, has received approval of ADCETRIS from the Japanese Ministry of Health, Labour and Welfare for the treatment of patients with CD30-positive relapsed or refractory Hodgkin lymphoma and anaplastic large cell lymphoma. As a result, Seattle Genetics will receive two milestone payments from Takeda totaling $9M upon final pricing agreement in Japan. ADCETRIS is an antibody-drug conjugate directed to CD30, a defining marker of classical HL and known to be expressed in some types of non-Hodgkin lymphoma, including ALCL. The approval of the new drug application was based on two global pivotal phase 2 clinical trials of ADCETRIS, as well as a phase 1/2 clinical trial conducted in Japan, for patients with relapsed or refractory CD30-positive HL and ALCL. In March 2012, the Japanese MHLW granted ADCETRIS orphan drug designation for the treatment of patients with HL and ALCL, which triggered priority review in Japan.
News For SGEN From The Last 14 Days
Check below for free stories on SGEN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 9, 2014
10:02 EDTSGENOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
05:59 EDTSGENSeattle Genetics upgraded to Buy from Neutral at UBS
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use